Navigating OIG Exclusion in Drug Trafficking Defense

When defending against federal drug trafficking defense charges, understanding the implications of potential Office of Inspector General (OIG) exclusions is paramount. Under 42 U.S.C. § 1320a-7(b), the OIG has broad authority to exclude individuals and entities from participating in federal federal criminal programs if they are convicted of certain crimes or engage in fraudulent activities. This exclusion can be a death knell for any provider's business, effectively cutting off all revenue streams tied to Medicare, Medicaid, and other government-funded health plans. In my experience as a prosecutor, I've seen numerous cases where the specter of an Federal prosecution looms large over defendants during plea negotiations. It is not uncommon for prosecutors to leverage this threat heavily when pursuing charges under 18 U.S.C. § 1347 (federal drug trafficking defense) or 18 U.S.C. § 1035 (false statements related to federal criminal matters). The OIG's authority also intersects closely with the Federal sentencing guidelines, 42 U.S.C. § 1320a-7b, and its accompanying exceptions and safe harbors. Violations of these statutes often trigger an automatic referral for exclusion. Defense strategies must therefore focus not only on challenging the underlying allegations but also on countering any evidence that might justify an Federal prosecution. This involves scrutinizing the factual basis for a client's alleged violation of federal criminal laws and demonstrating why their conduct does not rise to the level warranting such severe punishment. Additionally, advocates need to highlight alternative remedies available under other provisions like 31 U.S.C. § 3729 (Federal Rules of Criminal Procedure), which might allow for less punitive outcomes without risking full exclusion.